D
Deciphera Pharmaceuticals
Biotech & Life Sciences · Waltham, United States · Founded 2003 · IPO 2017
A clinical-stage biopharmaceutical company focused on improving the lives of cancer patients by tackling key mechanisms of drug resistance that limit the effectiveness of many cancer therapies MoreLess
Deciphera Pharmaceuticals, a member of ONO Group, is a biopharmaceutical company dedicated to discovering, developing, and commercializing new medicines aimed at improving the lives of cancer patients. The company leverages its proprietary switch-control kinase inhibitor platform and extensive expertise in kinase biology to create a broad portfolio of targeted therapies. Deciphera primarily serves the oncology market, focusing on patients with various forms of cancer. The business model revolves around the research and development of novel drugs, followed by clinical trials and regulatory approvals, leading to commercialization. Revenue is generated through the sale of these approved medicines and potential partnerships or licensing agreements with other pharmaceutical companies.
Keywords: biopharmaceutical, cancer, kinase inhibitors, oncology, drug development, clinical trials, commercialization, kinase biology, proprietary platform, oncology market.
Talent graph
Deciphera Pharmaceuticals's talent
Source: Dealroom Talent Intelligence.
Investors
8 investors on Deciphera Pharmaceuticals's cap table
Sourced from Dealroom's funding and investor records.







Global footprint
Where Deciphera Pharmaceuticals has talent and traffic
team presence
across markets
Patent intelligence
Deciphera Pharmaceuticals’s patent portfolio
111 active families in the valuation dataset.
Source: Dealroom Patent Intelligence · PatSnap. Portfolio estimates and the family records below have different coverage.
Market sentiment
What the market is saying about Deciphera Pharmaceuticals
An AI-synthesized read of the highest-engagement posts about Deciphera Pharmaceuticals on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Deciphera Pharmaceuticals on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.